Journal: Signal Transduction and Targeted Therapy

Article Title: Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

doi: 10.1038/s41392-024-02002-z

Figure Lengend Snippet: Representative completed and ongoing clinical studies (immunotherapy)

Article Snippet: , , BNT142 , CLDN6-positive solid tumors , T-cell-engaging bispecific antibody against CLDN6 and the T-cell receptor–associated molecule CD3 , LNPs , Intravenous bolus/infusion , 2022-03-28 , Phase I/II , Recruiting , / , NCT05262530 , BioNTech SE , .

Techniques: Virus, Injection, Membrane, Adjuvant, Activity Assay, Plasmid Preparation, Saline, Electroporation, Transfection, Inhibition

Journal: Heliyon

Article Title: The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases

doi: 10.1016/j.heliyon.2024.e26971

Figure Lengend Snippet: List of all conducted clinical trials for mRNA-based treatment of cancers (Until Jan 2024).

Article Snippet: 104 , NCT05262530 , Encodes a Monoclonal Antibody Against CLDN6 (BNT142) , In vivo , Solid Tumors , Monotherapy , Phase I/II (2022) , 288 , Adults (≥18) , BioNTech SE , United States Singapore Spain , Recruiting.

Techniques: Clinical Proteomics, In Vivo, Ex Vivo, Immunopeptidomics, Adjuvant, Isolation, Membrane, Mutagenesis, Transplantation Assay, Derivative Assay, Comparison, Vaccines, Knock-Out, Modification

Journal: Advanced Science

Article Title: Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation

doi: 10.1002/advs.202204335

Figure Lengend Snippet: Exosomes genetically engineered with divalent mAbs specially targeting CD3+ T cells and EGFR+ tumor augment T‐cell mediated anti‐tumor immunity. a) A scheme illustrating the preparation of α CD3 and α EGFR expressing exosomes (defined as SMART‐Exos). b) Confocal images of Jurkat T cells and MDA‐MB‐468 cells (red) linked by SMART‐Exos (green). c) Immunodeficient NSG mice were inoculated with MDA‐MB‐468 cells subcutaneously, followed by intraperitoneal injection of human PBMCs. The next day, mice were intravenously received α CD3/ α EGFR SMART‐Exos or PBS for six times with an interval of 2 days. a–c) Reproduced with permission. [ ⁹³ ] Copyright 2018, American Chemical Society.

Article Snippet: [ ] Along with these therapeutic mRNA cancer vaccines, BioNTech's product pipelines on clinical program include LNP‐mRNA products encoding antigen specific therapeutic mAbs (BNT141 and BNT142) or cytokines (BNT151, BNT152, and BNT153), which are currently being assessed in patients with solid tumors.

Techniques: Expressing, Injection

Journal: Advanced Science

Article Title: Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation

doi: 10.1002/advs.202204335

Figure Lengend Snippet: Multiple specific T cell nano‐engagers increase the half‐life of therapeutic mAbs and prevent tumor escape caused by antigen loss, conferring improved cancer immunotherapy. a) Illustrated are engineered different T cell nanoengagers as indicated and bispecific T cell nanoengagers‐mediated tumor killing. b) The biodistributions of adoptive human T cells and c) multiple myeloma progression curves in NSG mice received with different nanoengagers as indicated in (a). a–c) Reproduced with permission. [ ⁹⁴ ] Copyright 2021, Nature Publishing Group.

Article Snippet: [ ] Along with these therapeutic mRNA cancer vaccines, BioNTech's product pipelines on clinical program include LNP‐mRNA products encoding antigen specific therapeutic mAbs (BNT141 and BNT142) or cytokines (BNT151, BNT152, and BNT153), which are currently being assessed in patients with solid tumors.

Techniques:

Journal: Advanced Science

Article Title: Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation

doi: 10.1002/advs.202204335

Figure Lengend Snippet: Checkpoint inhibitor anti‐CD47 mAbs and anti‐cancer small drugs co‐formed in the liposome nanoparticles enable targeting modulation of TAMs for significantly improved treatment of TNBC. Illustrated are a) increased TAMs in TNBC promoting tumor progression, b) the key components of engineered PTX‐ILips (immune liposomes) and therapeutic mechanisms against TNBC. c) A TEM image of ILips. Scale bar: 50 nm. d) Confocal images of cells treated with different formulations in the presence or absence of MMP2. Red indicates α CD47 and green indicates liposomes. Scale bar: 20 µm. e) Mice with established MDA‐MB‐231 tumor (around 100 mm 3 ) received different treatments as indicated. Shown are the individual tumor growth curves. a–e) Reproduced with permission. [ ¹¹² ] Copyright 2021, American Chemical Society.

Article Snippet: [ ] Along with these therapeutic mRNA cancer vaccines, BioNTech's product pipelines on clinical program include LNP‐mRNA products encoding antigen specific therapeutic mAbs (BNT141 and BNT142) or cytokines (BNT151, BNT152, and BNT153), which are currently being assessed in patients with solid tumors.

Techniques: Liposomes

Journal: Advanced Science

Article Title: Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation

doi: 10.1002/advs.202204335

Figure Lengend Snippet: The most recent advanced nanoformulations targeting immune cells for cancer therapy

Article Snippet: [ ] Along with these therapeutic mRNA cancer vaccines, BioNTech's product pipelines on clinical program include LNP‐mRNA products encoding antigen specific therapeutic mAbs (BNT141 and BNT142) or cytokines (BNT151, BNT152, and BNT153), which are currently being assessed in patients with solid tumors.

Techniques: Polymer, Activation Assay, Lysis, Adjuvant, Activity Assay, Transfection, Immunopeptidomics, Membrane, Expressing, Plasmid Preparation, Control, Drug discovery